These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments, and royalty payments as part of an agreement.
NeuroSense anticipates receiving terms from these discussions in the fourth quarter of 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what the final terms would be, if any, or that a definitive agreement will be reached.
In August, NeuroSense Therapeutics released 12-month iron biomarker data from its PARADIGM Phase 2b study for PrimeC in ALS patients.
The results demonstrated the target engagement of PrimeC in iron regulation, which is linked to disease mitigation and improved survival.
These changes in iron metabolism align with improved clinical outcomes. Patients on PrimeC maintained better functionality and survival rates than those on placebo.
Specifically, the intent to treat analysis at 12 months revealed a difference of 6.5 points in the ALSFRS-R, representing a 36% improvement and a statistically significant P value of 0.009.
In addition, at 12 months, participants on PrimeC demonstrated 43% better survival than those initially on placebo.
Price Action: NRSN stock closed at $0.74 on Tuesday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
